208 related articles for article (PubMed ID: 37524814)
21. Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens.
Nunes JJ; Pandey SK; Yadav A; Goel S; Ateeq B
Neoplasia; 2017 Apr; 19(4):333-345. PubMed ID: 28319807
[TBL] [Abstract][Full Text] [Related]
22. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
23. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
24. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
25. A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo.
Mi YY; Ji Y; Zhang L; Sun CY; Wei BB; Yang DJ; Wan HY; Qi XW; Wu S; Zhu LJ
Cell Death Dis; 2023 Jan; 14(1):67. PubMed ID: 36709328
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
27. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
28. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
29. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
30. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
31. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
34. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
[No Abstract] [Full Text] [Related]
35. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
36. Determining the prognostic significance of IKKα in prostate cancer.
Montes M; MacKenzie L; McAllister MJ; Roseweir A; McCall P; Hatziieremia S; Underwood MA; Boyd M; Paul A; Plevin R; MacKay SP; Edwards J
Prostate; 2020 Oct; 80(14):1188-1202. PubMed ID: 33258506
[TBL] [Abstract][Full Text] [Related]
37. NF-kappaB regulates androgen receptor expression and prostate cancer growth.
Zhang L; Altuwaijri S; Deng F; Chen L; Lal P; Bhanot UK; Korets R; Wenske S; Lilja HG; Chang C; Scher HI; Gerald WL
Am J Pathol; 2009 Aug; 175(2):489-99. PubMed ID: 19628766
[TBL] [Abstract][Full Text] [Related]
38. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
39. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
Jeong JH; Park SJ; Dickinson SI; Luo JL
Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
[TBL] [Abstract][Full Text] [Related]
40. Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer.
Pawar A; Gollavilli PN; Wang S; Asangani IA
Cell Rep; 2018 Feb; 22(9):2236-2245. PubMed ID: 29490263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
